HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer

Completed · Phase 1

Conditions studied: Breast Cancer, Lung Cancer, Ovarian Cancer

In brief

RATIONALE: Vaccines made from the HER2/neu antigen may make the body build an immune response and kill tumor cells. Colony-stimulating factors such as GM-CSF increase the number of immune cells found in bone marrow or peripheral blood. PURPOSE: Phase I trial to study the effectiveness of HER-2/neu vaccine plus GM-CSF in treating patients who have stage III or stage IV breast cancer, stage III or stage IV ovarian cancer, or stage III or stage IV non-small cell lung cancer.

Key facts

Study ID

NCT00003002

Run by

University of Washington

People needed

60

Starts

1996-04-01

Expected to finish

2004-01-01

Last updated by the study team

2019-02-27

Who can join

Age: any, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Washington School of Medicine — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.